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Abstract: Oxetanes are four-membered ring oxygen het-
erocycles that are advantageously used in medicinal
chemistry as modulators of physicochemical properties of
small molecules. Herein, we present a simple method for
the incorporation of oxetanes into proteins through che-
moselective alkylation of cysteine. We demonstrate
a broad substrate scope by reacting proteins used as
apoptotic markers and in drug formulation, and a thera-
peutic antibody with a series of 3-oxetane bromides, ena-
bling the identification of novel handles (S-to-S/N rigid,
non-aromatic, and soluble linker) and reactivity modes
(temporary cysteine protecting group), while maintaining
their intrinsic activity. The possibility to conjugate oxetane
motifs into full-length proteins has potential to identify
novel drug candidates as the next-generation of peptide/
protein therapeutics with improved physicochemical and
biological properties.
Oxetanes are heterocyclic 1,3-propylene oxide moieties[1] that
constitute the core structure of many biologically active natu-
ral products (e.g. the antibiotic oxetin) and synthetic com-
pounds (e.g. carbonyl bioisosters, agrochemicals, and peptido-
mimetics, among others).[2] They have emerged as important
motifs in drug discovery due to the modulation of the physico-
chemical properties of the molecule to which they are at-
tached.[3] Typically, oxetanes increase water solubility, metabol-
ic stability, and reduce lipophilicity while maintaining their
parent selectivity without altering activity (Figure 1). Despite
the many examples reported for the introduction of such
motifs in small molecules, their application to modify complex
biomolecules, such as proteins/antibodies (beyond peptidomi-
metics),[4] is largely unprecedented.
The aim of the present proof-of-principle study is to explore
methods for the chemoselective introduction of oxetane moi-
eties into proteins and antibodies by alkylation of the sulfhydr-
yl group of the side chain of cysteine (Cys) with a series of
structurally similar 3-oxetane bromides. We reasoned that in-
vestigation of oxetane reagents (e.g. secondary vs. primary hal-
ides and 3-mono vs. 3,3-disubstituted) and their reactivity to-
wards a number of different protein scaffolds would test the
generality of this site-selective protein modification method for
the preparation of homogeneous proteins.[5] We envisaged our
method would allow access to a new family of protein conju-
gates with potential therapeutic applications,[6] for example, by
enhancing ligand–protein binding since the oxetane ring
serves as a hydrogen-bond acceptor.[7]
We began our investigation by exploring the site-selective
incorporation of the 3-S-oxetane motif into proteins by react-
ing inexpensive, commercially available 3-bromooxetane
1 with single-Cys mutants of the C2A domain of Synaptotag-
min-I Cys95 (C2Am) and Annexin-V Cys315 (AnxV) as represen-
tative examples of specific apoptotic protein markers (Figure-
s 2a and 2b).[8] Incubation of C2Am with 1 in 50 mm sodium
phosphate buffer (NaPi) at pH 11 with up to 20% DMF, to
ensure oxetane’s solubility, afforded expected Cys-to-oxetane
alkylation product 2 in >95% conversion (via an SN2 reaction)
as determined by liquid chromatography electrospray ioniza-
tion mass spectrometry (LC-ESI-MS) after 30 h at 37 8C. Remark-
ably, and unlike most of the alkylating electrophiles commonly
used for “on protein” Cys alkylation (typically primary C(sp3)
halides), the present transformation using a secondary C(sp3)
bromide represents a stereoelectronically challenging, yet suc-
cessful example of a constrained small oxygen heterocycle al-
kylation, which may account for the “harsh” conditions em-
ployed. The modified protein was identified by LC-ESI-MS,
which showed a single peak (16279 Da) with a mass shift cor-
responding to the addition of a single 3-oxetane unit (+
57 Da). Negative Ellman’s test and peptide mapping/MS2 analy-
sis revealed the alkylation proceed with exquisite chemoselec-
tivity at Cys95 (Figure 2c and the Supporting Information, Fig-
ures S1–S5). Experiments to further evaluate putative lysine
(Lys) cross-reactivity were conducted with single Lys-peptide
S1 and 3-bromooxetane 1 using conditions similar to those
employed for “on protein” Cys alkylation (50 mm NaPi at pH 11
with 20% DMF). No reactivity was noticed after 36 h at 37 8C
as monitored by 1H NMR (Supporting Information, Figure S77).
Importantly, the 3-S-oxetane motif proved stable upon incu-
bation with human plasma (37 8C, 24 h) and in the presence of
endogenous thiols such as reduced glutathione (GSH) (20 mm,
37 8C, 24 h), which are prerequisite conditions for in vivo appli-
cations. Identical stability was also noticed upon incubation
with other S- or N-nucleophiles (b-mercaptoethanol (BME),
PhSH, bGalSNa, and BnNH2) under forcing conditions (50 mm
NaPi at pH 4.5–11 with/without 20% CH3CN, 37 8C, up to 24 h).
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Additionally, additives known to promote oxetane ring-open-
ing polymerization[9] were also tested without success. These
included oxophilic metallic complexes (Y(OTf)3 and
MgCl2·6H2O) and organocatalytic promoters (urea and thiour-
ea) (Supporting Information, Figures S6–S21). The inertness of
the oxetane ring towards nucleophiles is in line with previous
studies that described their lack of geno/cytotoxicity and mu-
tagenicity, unlike that of epoxides and b-lactones, because
they do not act as alkylating agents at physiological pH.[10]
Likewise, other proteins such as AnxV reacted similarly at
pH 11 with 10% DMF and expected product 3 was obtained in
>95% conversion, thus demonstrating the robustness of this
alkylation protocol to modify this widely used apoptotic pro-
tein marker (Figure 2b). Finally, the impact of such a modifica-
tion and reaction conditions in protein’s structure and function
was evaluated using circular dichroism (CD) and surface plas-
mon resonance (SPR), respectively.[8] The chemoselective incor-
poration of the 3-S-oxetane motif in 2 is mild as determined
by CD analysis, which showed no structure alteration between
native and modified proteins (Supporting Information, Fig-
ure S80). Additionally, despite the SPR functional assay for
C2Am vs. C2Am-3-S-Ox 2 shows that its intrinsic binding activi-
ty against phosphatidylserine (PS), an internal membrane lipid
externalized during apoptosis, is only partially eroded (60% ac-
tivity is maintained), differences in its binding mechanism is
noticed from the analysis of the binding and dissociation
curves (Figure 2d).
Having established conditions for efficient site-selective in-
corporation of the 3-oxetane motif into Cys-tagged proteins,
we explored the extension of this approach to other oxetanes.
We continued by evaluating the homobifunctional electrophile
3,3-bis(bromomethyl)oxetane 4 (Figure 3). We anticipate the
facile alkylation of Cys due to the a priori more accessible, re-
active primary C(sp3) bromide will enable efficient desymmetri-
zation of 4, thus providing a platform to chemoselectively in-
corporate an electrophilic handle (BrCH2-S-oxetane) into a pre-
defined site of proteins. This handle is amenable to a second
round of chemical modification (via an SN2 reaction) after incu-
Figure 1. The oxetane motif present in small molecules (state of the art) and its application in site-selective chemical protein modification (this work).
Figure 2. Selective incorporation of the 3-S-oxetane motif into proteins. a) General strategy with 1. b) Protein scope with C2Am and AnxV. c) MS2 spectrum of
the m/z 511.25 doubly charged ion of the tryptic peptide VPYCELGGK, containing the 3-S-oxetane modification at the original Cys95 residue in 2 ; the frag-
ment ions generated are consistent with the mass of the modification. d) Biacore SPR analysis of C2Am and 2 against PS; the data represent meanSD ob-
tained from two independent experiments performed in duplicate.
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bation with an appropriate nucleophile (e.g. post-translational
modifications, cytotoxics, and spectroscopic tags, among
others) (Figure 3a). Indeed, this is a difficult task and very few
chemical methods allow for the precise installation of electro-
philic reacting points on a single residue,[11] which is typically
achieved by genetic encoding protocols.[12] Thus, reaction of 4
with C2Am in NaPi (50 mm, pH 8) with 10% DMF afforded 5 in
>95% conversion as determined by LC-ESI-MS after 5 h at
37 8C. Fine-tuning of the reaction conditions and using pH 11
reduced the reaction time to only 2 h, while maintaining che-
moselectivity as confirmed by negative Ellman’s test and
1H NMR experiments with Lys-peptide S1 (Supporting Informa-
tion, Figures S22–S26 and S78). The protein scope was further
expanded to AnxV that reacted similarly at pH 11 with 10%
DMF to obtain 6 in >95% conversion (Figure 3b and Support-
ing Information, Figures S54 and S56). We next set up to evalu-
ate the incorporation of several S- and N-nucleophiles taking
advantage of the flexible introduction of the privileged 3-bro-
momethyl-3-S-oxetane handle. This represents a unique exam-
ple of spiro, heterobifunctional S-to-S/N linker[13] that enables
the diversity-oriented introduction of several nucleophiles from
a single Cys mutant.[14] To this end, 5 was incubated with the
S-nucleophiles bGalSNa, BME, and PhSH as representative ex-
amples of protein glycosylation, aliphatic, and aromatic moiet-
ies, respectively as well as BnNH2 as an N-nucleophile present
in several drug fragments to afford 7a–d in >95% conversion
(Figure 3c). Extending the reaction time once the alkylation is
completed (e.g. up to 15 h with PhSH) did not show any no-
ticeable degradation (Supporting Information, Figures S27–
S33). Moreover, similar to that observed with the 3-S-oxetane
motif, S-to-S/N oxetane linker in 7c also proved stable upon in-
cubation with human plasma (37 8C, 24 h) and GSH (20 mm,
37 8C, 24 h) (Supporting Information, Figures S34 and S35),
which reinforces its application as a novel linker for stable, co-
valent protein modification (e.g. including disulfide stapling).[5]
The display of bGalS as a representative example of carbohy-
drate epitope was further studied by molecular dynamics (MD)
simulations and the result compared to a general aliphatic
linker with the same number of carbons, obtained by thiol-ene
chemistry at S-allyl cysteine (Sac) (Figure 3d).[15] Interestingly,
the oxetane linker in 7a proved to be a more rigid scaffold
than that in 8 for the presentation of bGalS as determined by
the analysis of the angle between Ca-Cb-C1 where a major
population is observed. Taken together, we believe this rigid,
non-aromatic, and soluble linker will be advantageous, for ex-
ample, in the development of homogeneous carbohydrate-
Figure 3. Selective incorporation of an S-to-S/N oxetane linker on proteins. a) General strategy with 4. b) Protein scope with C2Am and AnxV. c) Nucleophile
scope with 5. d) Analysis of the flexibility of S-to-S/N oxetane linker in 7a (lower panel) vs. a standard 3C-linear linker in 8 (upper panel) obtained from 100 ns
MD simulations. The data presented in this Figure corresponds to the average structure of both linkers through the simulations.
Chem. Eur. J. 2017, 23, 1 – 8 www.chemeurj.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim4&&
 These are not the final page numbers!
Communication
based vaccine conjugates, hopefully, with reduced anti-linker
response.[16]
Encouraged by these results, we next evaluated the use of
3-(bromomethyl)oxetane 9 (Figure 4). Experiments with
a series of proteins (C2Am, AnxV, and recombinant human
serum albumin (rHSA)) and one antibody (Trastuzumab) re-
vealed the application of this moiety as a novel temporary pro-
tecting (PG) group for Cys-containing biomolecules[17] (via the
following full sequence Cys-protection!SCH2-Ox!Cys-depro-
tection) (Figures 4a and 4b). Unlike previous reactions with 3-
oxetane bromides 1 and 4 that necessitated up to pH 11 or
prolonged reaction times to reach completion, the alkylation
with 9 proceed smoothly at pH 8 (for C2Am) and pH 9 (for
AnxV), respectively to afford 10 and 11 in uniformly complete
conversions with a mass difference corresponding to the incor-
poration of a single CH2-oxetane moiety (+71 Da). Negative
Ellman’s test confirmed the chemoselectivity at Cys95 in C2Am
and Cys315 in AnxV (Supporting Information, Figures S36, S37,
S57, and S58). rHSA (Albumedix Recombumin),[18] an approved
ingredient for the manufacture of human therapeutics that
possess multiple Cys residues, 17 structurally relevant disulfides
and a single Cys at position 34, gave the expected monoalkyla-
tion product 12 (25% conv.) upon incubation with 50 equiv of
9 in NaPi (50 mm, pH 8) with 10% DMF as determined by LC-
ESI-MS after 2 h at room temperature. However, the addition
of several 3-methyloxetane units (+71 Da) was observed after
prolonged reaction times by increasing the equivalents of 9 (>
50 equiv) and warming the reaction up to 37 8C. We reasoned
this might be attributed to the reaction of 9 with partially re-
duced disulfides (Supporting Information, Figures S64–S67).[19]
Similar results are also obtained with the monoclonal antibody
(mAb) Trastuzumab containing several structural disulfides
(Figure 5a).[20]
We then examined the stability of 3-S-monomethyl oxetane
proteins. Incubation of 10 with 100 equiv of BnNH2 in NaPi
(50 mm, pH 8) unexpectedly resulted in the full recovery of the
original Cys moiety after 2 h at 37 8C (Figure 4c). Interestingly,
a conceptually similar N-dealkylation reaction by oxidative
cleavage of the CH2 bridge was found to be the main metabo-
lization product in 3-monomethyl oxetanes.[21] This study also
suggests, as we found in our work with the 3,3-disubstituted
analogue, the introduction of bulky gem-dimethyl substituents
increases the stability of the oxetane. A putative S-dealkylation
scenario in which the nucleophile attacks the alpha carbon
(Ca) of the oxetane, releasing Cys as a leaving group perhaps
with the participation/anchimeric assistance of the non-bond-
ing electron pair of the oxygen might account for the reactivity
observed, although alternative mechanisms (e.g. oxidative
cleavage with atmospheric O2)
[22] cannot be discarded. With
these preliminary conditions in hand, the scope of the reaction
was evaluated with a range of S-, N-, and P-nucleophiles (BME,
PhSH, bGalSNa, BnNH2, and tris(2-carboxyethyl)phosphine
(TCEP)) and proteins (10 and 11). Despite starting Cys-proteins
(C2Am and AnxV) were recovered in up to >95% conversion,
the rate of this transformation seems to be dependent on the
combination of protein/nucleophile/conditions (Supporting In-
formation, Figures S38–S47 and S59–S61). For example, depro-
tection of 10 was slower with both TCEP (9 h) and PhSH (22 h),
necessitating a large excess of nucleophile (10,000 equiv) at
37 8C to reach completion, whereas bGalSNa required only 5 h
(at pH 8) or 2 h (at pH 11). Similarly, AnxV was obtained from
11 after incubation with 100 equivalents bGalSNa in NaPi
(50 mm, pH 9) after only 1 h at 37 8C. Controls to demonstrate
how oxetanes modulates the electrophilic character of the Ca
enabling the S-dealkylation when treated with excess S-, N-,
and P-nucleophiles were carried out using the Sac handle[23] as
a stable 3C-surrogate of the S-methyloxetane unit (SCH2-Ox).
Sac-containing proteins C2Am S2 and AnxV S3 were subjected
to the same S-dealkylation conditions and starting materials
were recovered unaltered. Thus, our preliminary findings sug-
gest a role of the methyloxetane moiety in the nucleophile-in-
duced deprotection step, at least on full-length proteins (Fig-
Figure 4. Selective incorporation of the SCH2-3-oxetane motif into proteins as a Cys temporary protecting group. a) General strategy with 9. b) Protein scope
with C2Am, AnxV, and rHSA. c) Schematic representation of the deprotection step (SCH2-Ox!Cys) with several P-, N-, and S-nucleophiles and unreactive con-
trols using Sac (see the Supporting Information for details). §Multiple additions observed upon incubation with >50 equiv of 9.
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ure 4c and Supporting Information, Figures S48, S49, S62, and
S63).[24]
Finally, the utility of our protocol was extended to the rever-
sible modification of Trastuzumab; a mAb used in the clinic for
the treatment of HER2+ metastatic breast and gastric cancers.
We found the Cys-engineered Trastuzumab analog (Thiomab
4D5 LC-V205C)[20] reacted with 9 in NaPi (50 mm, pH 8) with
10% DMF to afford modified 13 containing several (3-methyl-
oxetane)n units (+71n Da) in the light chain as determined by
LC-ESI-MS after 5 h at room temperature (Figure 5a and SI, Fig-
ures S68 and S69).[25] Similarly to 3-oxetane bromides 1 and 4,
1H NMR experiments with 9 and single Lys- and single Cys-pep-
tides S1 and S4, respectively demonstrated the introduction of
these multiple 3-methyloxetane units is due to alkylation of
the free engineered Cys together with those resulting from in-
efficient re-oxidation of structural disulfides[20] rather than for
Lys cross-reactivity (Supporting Information, Figure S79).
The (SCH2-Ox)-to-Cys deprotection in 13 was triggered by
TCEP, BnNH2, or BME and represents a successful metal/light-
free example of a protection–deprotection sequence on an
intact IgG mAb (Supporting Information, Figures S70–S73). We
then investigated the influence of incorporation/removal of
SCH2-Ox on mAb’s function by bio-layer interferometry (BLI)
analysis and compared its activity before and after modifica-
tion. We found, the binding affinity is maintained along the
entire protection-deprotection cycle with their binding con-
stants remaining within the same nanomolar range (Figure 5b
and Supporting Information, Figures S83 and S84). We expect
this protocol will find use as a tool for transient, site-selective
manipulation of Cys on proteins and antibodies.[26]
In summary, we disclosed an operationally simple and ad-
vantageous method for the chemoselective introduction of ox-
etane moieties into proteins through alkylation of Cys residues.
We validated this mild transformation on a series of proteins
and antibodies, which maintained their inherent activities.
Screening of oxetane variants enabled the discovery of novel
handles (spiro S-to-S/N linker) and reactivity modes (temporary
Cys-PG). This work provides the basis for the development of
novel oxetane reagents and complements current methods for
site-selective chemical protein/peptide modification.[5] We an-
ticipate the knowledge derived from this thorough proof-of-
principle study will help in the selection of reaction conditions
suitable for introducing other strained heterocyclic motifs
opening new horizons in the field of protein engineering and
biological therapeutics.[6]
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Site-Selective Modification of Proteins
with Oxetanes Oxe-tag-it: Chemoselective incorpora-
tion of oxetane motifs into proteins/an-
tibodies enables the identification of
novel handles and reactivity modes
with potential in the field of protein en-
gineering and biological therapeutics.
Crossing bridges : The frontispiece shows a protein
modified with a sugar through an oxetane and in the
background, the Cambridge Mathematical Bridge (artwork
designed by Claudia Flandoli). The use of an oxetane bridge
that connects a synthetic molecule, in this case a sugar, and
a protein, is the novelty of the work described in the
Communication by O. Boutureira, G. J. L. Bernardes, and co-
workers on page &&ff.
Chem. Eur. J. 2017, 23, 1 – 8 www.chemeurj.org  2017 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim8&&
 These are not the final page numbers!
Communication
